LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum Magnesium Levels Associated with CAP Mortality

By LabMedica International staff writers
Posted on 07 Jan 2019
Image: The Dimension EXL 200 integrated chemistry system (Photo courtesy of Siemens Healthcare).
Image: The Dimension EXL 200 integrated chemistry system (Photo courtesy of Siemens Healthcare).
Community acquired pneumonia (CAP) is a common illness affecting hundreds of millions worldwide, with increasing hospital admissions throughout the years mainly due to the aging population. It is a major cause of mortality and morbidity in all age groups, especially the elderly.

Magnesium deficiency has been associated with a number of clinical manifestations such as arrhythmias, cardiac insufficiency, sudden death, muscle weakness, bronchospasm, tetany, seizures, as well as hypokalemia, hypocalcaemia, hyponatremia, and hypophosphatemia. Hypermagnesemia may cause severe symptomatic hypotension, bradycardia and ECG changes like wide QRS.

Scientists at the Rambam Health Care Campus (Haifa, Israel) and their colleagues retrospectively reviewed between January 1, 2010, and December 31, 2016, the data of 4,708 patients diagnosed with CAP at discharge; 3,851 patients had magnesium levels within 48 hours, and 55% were males and the median age was 72 years old. Participants were analyzed retrospectively in order to identify the risk factors for a primary endpoint of 30-day mortality.

The Charlson’s comorbidity score was calculated based on data collected; laboratory values (first values within 48 hours): Hemoglobin (Hb), White blood cell count (WBC), red blood cell distribution width (RDW), pH, partial pressure of carbon dioxide (pCO2), serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin. Hematological values were measured using the Advia 120 Hematology Analyzer. Serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin were measured on admission using Siemens’ Dimension Integrated Chemistry System; PH, bicarbonate, partial pressure of CO2 and lactate were measured using GEM premier 3500.

The team reported that blood urea nitrogen (BUN) > 20 mg/dL, hypoalbuminemia, and abnormal levels of magnesium were all associated with increased risk of 30-day mortality. Normal magnesium levels were associated with the lowest mortality rate (14.7%). Notably, within the normal levels, high normal magnesium levels (2.0 to 2.4 mg/dL) were correlated with higher mortality rates (30.3%) as compared to levels that ranged between 1.35 to 2 mg/dL (12.9%). Hypomagnesemia and hypermagnesemia were both associated with excess of 30-day mortality, 18.4 and 50%, respectively. Normal levels of magnesium levels in their laboratory vary between 1.35 and 2.4 mg/dL.

The authors concluded that hypomagnesemia and hypermagnesemia on admission were associated with an increased rate of 30-day mortality among adult patients hospitalized with CAP. Interestingly, magnesium levels within the upper normal limits were associated with higher mortality. The study was published on December 27, 2018, in the journal BMC Infectious Diseases.

Related Links:
Rambam Health Care Campus

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240

Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more